HCR Wealth Advisors Takes Position in Eli Lilly And Co (NYSE:LLY)

HCR Wealth Advisors bought a new stake in Eli Lilly And Co (NYSE:LLY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,329 shares of the company’s stock, valued at approximately $217,000.

A number of other large investors have also recently modified their holdings of LLY. Stonebridge Financial Planning Group LLC raised its holdings in Eli Lilly And Co by 70.0% in the first quarter. Stonebridge Financial Planning Group LLC now owns 170 shares of the company’s stock valued at $25,000 after acquiring an additional 70 shares in the last quarter. Truvestments Capital LLC acquired a new position in shares of Eli Lilly And Co in the 1st quarter valued at $27,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Eli Lilly And Co in the 1st quarter valued at $34,000. Bainco International Investors acquired a new position in shares of Eli Lilly And Co in the 1st quarter valued at $34,000. Finally, Center for Financial Planning Inc. increased its holdings in shares of Eli Lilly And Co by 44.5% in the 1st quarter. Center for Financial Planning Inc. now owns 289 shares of the company’s stock valued at $40,000 after acquiring an additional 89 shares during the period. 77.32% of the stock is currently owned by hedge funds and other institutional investors.

LLY has been the topic of a number of recent research reports. Cantor Fitzgerald lifted their target price on shares of Eli Lilly And Co from $156.00 to $185.00 and gave the company an “overweight” rating in a report on Friday, April 24th. Zacks Investment Research cut their target price on shares of Eli Lilly And Co to $156.00 in a report on Wednesday, April 29th. Cowen lifted their target price on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Guggenheim raised shares of Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 target price on the stock in a report on Tuesday, June 16th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly And Co from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Wednesday, June 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $168.58.

Shares of NYSE LLY traded down $2.71 during trading on Friday, hitting $150.29. 5,342,109 shares of the company were exchanged, compared to its average volume of 2,630,266. The company has a market cap of $143.74 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 1.32 and a beta of 0.26. Eli Lilly And Co has a 1 year low of $101.36 and a 1 year high of $170.75. The firm’s fifty day moving average price is $160.88 and its 200 day moving average price is $148.62. The company has a debt-to-equity ratio of 4.37, a current ratio of 1.11 and a quick ratio of 0.86.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Thursday, July 30th. The company reported $1.89 EPS for the quarter, topping the consensus estimate of $1.58 by $0.31. The company had revenue of $5.50 billion for the quarter, compared to analyst estimates of $5.77 billion. Eli Lilly And Co had a net margin of 24.48% and a return on equity of 200.78%. The business’s revenue was down 2.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.50 EPS. On average, research analysts forecast that Eli Lilly And Co will post 7.3 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $0.74 per share. The ex-dividend date of this dividend is Thursday, August 13th. This represents a $2.96 annualized dividend and a dividend yield of 1.97%. Eli Lilly And Co’s payout ratio is currently 49.01%.

In other news, SVP Alfonso G. Zulueta sold 17,000 shares of Eli Lilly And Co stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $162.94, for a total transaction of $2,769,980.00. Following the completion of the transaction, the senior vice president now owns 39,646 shares of the company’s stock, valued at approximately $6,459,919.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 212,337 shares of Eli Lilly And Co stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $162.92, for a total value of $34,593,944.04. Following the transaction, the insider now directly owns 112,194,732 shares of the company’s stock, valued at approximately $18,278,765,737.44. The disclosure for this sale can be found here. Insiders have sold a total of 555,236 shares of company stock worth $91,393,391 over the last 90 days. Insiders own 0.09% of the company’s stock.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: What are the risks of holding treasury bonds?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.